AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03305848 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nitrostat 0.4Mg Sublingual Tablet
Description: Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes, and only if systolic blood pressure > 100 mmHg.
Study NCT01379846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-816+ DPT-TAKEDA
Description: TAK-816 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
Study NCT01379846 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB+ DPT-TAKEDA
Description: ActHIB 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
Study NCT04020523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI sequence
Description: The MR sequences added to the protocol are dedicated sequences for perfusion and diffusion imaging of breast lesion.
Study NCT01026246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo used will be normal saline (0.9 percent NaCl).
Study NCT01026246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBA-175 RII-NG Malaria Vaccine
Description: EBA-175 RII-NG malaria vaccine is supplied as a white, translucent, cloudy, nonparticulate liquid suspension in single-dose clear glass vials pre-mixed with Adju-Phos aluminum phosphate adjuvant. Each 2-mL vial of EBA-175 RII-NG vaccine contains: 0.7 mL (0.5 mL per dose) EBA-175 RII-NG, at the required dose concentration, 5 percent sucrose, 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant, sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride), and no preservative.
Study NCT01574885 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment consist of 10 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
Study NCT01534195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Sodium Phosphate Ophthalmic Solution 1%
Description: One drop in each eye, four times/day for 8 days.
Study NCT03282955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipidem
Description: Lipoplus i.v. lipid emulsion for parenteral nutrition
Study NCT03282955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipofundin MCT 20%
Description: Lipofundin MCT 20% i.v. lipid emulsion for parenteral nutrition
Study NCT02109172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02109172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02513862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous Platelet-Rich Plasma Harvest Technique
Description: 15 to 20 mL/kg of whole blood is collected before the administration of heparin from a large-bore central venous access,and is separated into red blood cells component and autologous platelet-rich plasma component by an autologous transfusion system(Sorin Group Electa Essential; Sorin Group Italia, Milan, Italy).
Study NCT04400162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usability of the CCT
Description: Evaluation of the usability of the provided training.
Study NCT04400162 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usability of the CCT
Description: Evaluation of the usability of the provided training.
Study NCT04400162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Changes in regards to the depressive disorder
Description: Evaluation of depressive symptoms and whether they change in regards to the provided training.
Study NCT04400162 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Changes in regards to the depressive disorder
Description: Evaluation of depressive symptoms and whether they change in regards to the provided training.
Study NCT04669119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bromelain/Boswellia Serrata Casperome
Description: Dietary supplement already commercialized based on Bromelain/Boswellia Serrata Casperome (Arm A and B), called Siben by Agaton
Study NCT01534195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tears Naturale II Ophthalmic Solution
Description: one drop in each eye, four times/ day (QID) for 8 days
Study NCT02669121 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NoV Placebo-matching Saline
Description: NoV placebo-matching saline (0.9% sodium chloride).
Study NCT04669119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Centella Asiatica/Vitamins
Description: Dietary supplement already commercialized based on Centella Asiatica/Vitamins (Arm B), called Kardinal V by Agaton
Study NCT02669121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NoV GI.1/GII.4 Bivalent VLP Vaccine
Description: NoV bivalent VLP vaccine, adjuvanted with 500 µg aluminum as Al(OH)3.
Study NCT00549575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L ARG
Description: Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories).
Study NCT00549575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After double blind randomization, patients received a placebo.
Study NCT03516656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard heparin dose
Description: Patients will be placed on heparin infusions per their surgeon's discretion.
Study NCT03516656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Real time heparin dose adjustment
Description: Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
Study NCT02463773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Diaphragmatic excursion ultrasound assessment
Study NCT02558777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent nurse-led intervention
Description: Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge. The intervention was carried out exclusively by the intervention nurses, and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain). Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs.
Study NCT03302637 — intervention group
Intervention type: OTHER
Intervention: 16S rRNA gene sequencing assay
Description: extraction of genomic DNA from oral samples using the Mobio DNA Isolation Kit. 16S rRNA amplicons covering variable regions V3 to V4 will be generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3')66 incorporating adapters and a sample barcode sequence at PI's lab. Amplicons will be sequenced with the Roche 454 FLX Titanium sequencing system at the NYU genome technology center, following the manufacturer's specifications.
Study NCT03191045 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI and concomitant perfused manometry of bowel motility
Description: We will carry out serial cine MRI of the bowel. At the same time we will record perfused manometry readings of the bowel in healthy adult participants.
Study NCT03153995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: soft tissue expansion
Description: Three surgeries will be carried out for group I patients:~* Soft tissue expansion (1st surgery); at baseline~* Alveolar ridge augmentation (2nd surgery); after five weeks~* Implant surgery (3rd surgery); after six months
Study NCT03153995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: soft tissue expansion
Description: Three surgeries will be carried out for group I patients:~* Soft tissue expansion (1st surgery); at baseline~* Alveolar ridge augmentation (2nd surgery); after five weeks~* Implant surgery (3rd surgery); after six months
Study NCT02748928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraShape Power
Description: Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
Study NCT02481245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: 30 patients with Bipolar I or Bipolar II disorder who are experiencing an acute bipolar depressive episode will be given bezafibrate XR 400 mg daily added on to adequate doses of an FDA-approved anti-manic medication.
Study NCT04669119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04669119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01379677 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rubidium-82
Description: Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use
Study NCT01379677 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sestamibi. reconstitution with sodium pertechnetate (99mTc)
Description: Maximum dose allowed per injection: 1000 MBq Intravenous Use
Study NCT02427412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline water
Description: 30 ml of Saline water injected into the knee capsula at the end of surgery.
Study NCT02427412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
Study NCT02427412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
Study NCT02347527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Implicit Priming
Description: A 10-minute implicit priming intervention, associating food images with images of positive or negative valence.
Study NCT02347527 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Implicit Priming
Description: A 10-minute implicit priming intervention, associating food images with images of neutral valence.
Study NCT02687841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120and pentoxyphylline (PTX)
Description: AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days pentoxyphylline 400mg QD PO x 10 days.
Study NCT02687841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentoxyphylline (PTX)
Description: pentoxyphylline 400mg QD PO x 10 days.
Study NCT03677271 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical Activity
Study NCT00298506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multitherapy
Description: Tacrolimus,4mg/d, MMF 1.0g/d
Study NCT03788109 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: device: combined solid state HRiM
Description: The HRiM catheter (Medical Measurement Systems, Enschede, The Netherlands) incorporating 36 pressure sensors, spaced at 2 cm in the stomach and esophagus and at 1 cm in the LES and upper esophageal sphincter (UES), and 16 impedance channels throughout the esophagus, will be placed transnasally, after topical anesthesia. Manometry will be used to record pressures in the stomach, the esophagus, the LES and the UES. In this way, it is possible to detect and characterize TLESRs, and to measure GA. The impedance channels will be used to measure bolus movement, and thus to detect and characterize gastro-esophageal reflux.
Study NCT03688048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light treatment lamp
Description: Exposure to bright white light (1 hour, 10 000 lux)
Study NCT03688048 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham negative ion generator
Description: Placebo treatment with deactivated negative ion generator (1 hour, audible hum, no ions emitted)
Study NCT03883373 — intervention group
Intervention type: PROCEDURE
Intervention: alveolar bone graft with cancellous bone and a cortical block
Description: alveolar bone graft with cancellous bone only
Study NCT03883373 — intervention group
Intervention type: PROCEDURE
Intervention: alveolar bone graft with cancellous bone only
Description: alveolar bone graft with cancellous bone only
Study NCT01657773 — intervention group
Intervention type: OTHER
Intervention: Ultrasound examination and Colonoscopy examination
Study NCT03439319 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyndMove®
Description: This FES therapy can be used as a short-term therapeutic intervention to help improve voluntary grasping function
Study NCT03439319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
Study NCT03310047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion, Lidocaine, 0.5%, 5 mL
Description: A catheter-based perineural infusion of 5 mL Lidocaine 0.5%
Study NCT03310047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion, Lidocaine, 0.5%, 10 mL
Description: A catheter-based perineural infusion of 10 mL Lidocaine 0.5%
Study NCT05475509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtually reality
Description: Before chemotherapy, saliva samples will be taken from the control group, Personal Information Form, State Anxiety Scale and Visual Analogue Scale (VAS) pre-test questionnaires will be applied to the patients who accepted to participate in the study, vital signs measurements will be made and post-test questionnaires will be applied at the 30th minute of chemotherapy, vital signs measurements will be made, and A saliva sample will be taken. In the experimental group, a saliva sample will be taken before chemotherapy.
Study NCT00521495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neodymium permanent magnet
Description: 3/4 diameter by 1/8 thick permanent magnet
Study NCT00521495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neodymium magnet
Description: A. 450 Gauss static magnetic field at target B. 150 Gauss static magnetic field at target C. 0 Gauss static magnetic field at target
Study NCT00521495 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neodymium magnet
Description: A. 450 Gauss static magnetic field at target B. 150 Gauss static magnetic field at target C. 0 Gauss static magnetic field at target
Study NCT00521495 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: magnet
Description: 0 Gauss magnets are worn every night during hours of sleep for 6 weeks.
Study NCT04115813 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Project YES! Youth Engaging for Success
Description: Participants in the intervention were offered once a month one-on-one meetings and group meetings with their assigned youth peer mentors over approximately six months. The participant's caregiver could also attend up to 3 caregiver support groups held at the clinic (every other month). In addition, intervention participants in the children's hospital were assessed (clinical and psycho social factors) for physical transition to an adult clinic. After midline data collection, the intervention arm went into a maintenance phase, meeting with the youth peer mentor every other month (3 times). Participants in the comparison arm after midline started the Project YES! intervention as described above. Primary analysis was conducted using midline data.
Study NCT04115813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project YES! Youth Engaging for Success
Description: Participants in the intervention were offered once a month one-on-one meetings and group meetings with their assigned youth peer mentors over approximately six months. The participant's caregiver could also attend up to 3 caregiver support groups held at the clinic (every other month). In addition, intervention participants in the children's hospital were assessed (clinical and psycho social factors) for physical transition to an adult clinic. After midline data collection, the intervention arm went into a maintenance phase, meeting with the youth peer mentor every other month (3 times). Participants in the comparison arm after midline started the Project YES! intervention as described above. Primary analysis was conducted using midline data.
Study NCT04057092 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement INergy-FLD
Description: INergy-FLD® is an immune modulating formula containing various ingredients including L-Arginine, whey protein isolate, and omega-6 fatty acid, aimed to attenuate excessive inflammatory responses without being immunosuppressive and to replenish nutrients that are depleted in a state of surgical stress, thereby enhancing the recovery process and decreasing the risk of infection. The volume of the beverage is 250mL per serving and patients will be asked to consume 3 servings periodically per day for 5 days prior to surgery and 5 days following surgery.
Study NCT01144832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ebastine
Description: 20 milligram capsule once daily
Study NCT01144832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: one capsule once daily
Study NCT02318264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Elastic tape placed over the skin
Study NCT03873532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 21-day treatment cycle).
Study NCT03873532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID, one dose each in the morning and evening, with a total dose of 2500 mg/m2 per day) for 2 weeks followed by 1 week of drug interruption. Each course of treatment will last 3 weeks. Capecitabine tablets should be swallowed with water within 30 minutes after a meal.
Study NCT02936765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy with prosthetic disc replacement / ESP.
Description: Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
Study NCT02936765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior cervical discectomy with prosthetic disc replacement / Squale.
Description: Anterior cervical discectomy, with the use of the Squale spacer (Manufacturer: OSD, Avignon, France) for the disc replacement.
Study NCT02993276 — intervention group
Intervention type: DEVICE
Intervention: Neurocap®
Description: NEUROCAP®, a bioresorbable nerve capping device based upon the NEUROLAC® nerve guide, is indicated to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic neuroma.
Study NCT04479046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PMMA crowns
Description: New type of pediatric crowns
Study NCT04479046 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PMMA crowns
Description: New type of pediatric crowns
Study NCT01843296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Injection of 50 mg of magnesium sulfate 50% (0.1 ml),intrathecally.
Study NCT01843296 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Lumbar puncture was performed in sitting position,at the one level above iliac crest. Using a median approach, a 25-G Quincke needle was introduced with the needle aperture directed laterally.
Study NCT00667537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 chloride (Xofigo®, BAY88-8223) injection
Description: Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration
Study NCT01199952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment group: receives counseling phone call intervention
Description: Subjects in the treatment arm will receive a phone call from a health educator to assist with contraception, 3 to 4 weeks after enrollment.
Study NCT01488175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tourniquet
Description: a tourniquet around the thigh is used during insertion of the TKA to achieve a bloodless environment
Study NCT01488175 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: no tourniquet
Description: a tourniquet around the thigh is not used during insertion of the TKA
Study NCT01843296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT01843296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl